Download PDF
Thromb Haemost 1997; 78(01): 327-333
DOI: 10.1055/s-0038-1657547
Oral contraceptives and thrombotic disease
Schattauer GmbH Stuttgart

Oral Contraceptives and Thrombotic Disease: Risk of Venous Thromboembolism

F M Helmerhorst
1   Department of Obstetrics, Gynecology and Reproductive Medicine, the Netherlands
,
K W M Bloemenkamp
1   Department of Obstetrics, Gynecology and Reproductive Medicine, the Netherlands
,
F R Rosendaal
2   Haemostasis and Thrombosis Research Centre, the Netherlands
3   Department of Clinical Epidemiology Leiden University and Leiden University Hospital, the Netherlands
,
J P Vandenbroucke
3   Department of Clinical Epidemiology Leiden University and Leiden University Hospital, the Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Jordan WM. Pulmonary embolism. Lancet 1961; 2: 1146-1147
    CrossrefPubMedGoogle Scholar
  • 2 Royal College of Practitioners. Oral contraception and thromboembolic disease. J Gen Coll Practit 1967; 13: 267-269
    PubMedGoogle Scholar
  • 3 Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism; a quantitative discussion of the uncertainties. J Int Med 1995; 238: 31-37
    CrossrefPubMedGoogle Scholar
  • 4 Fuertes dela Haba A, Curet JO, Pelegrina I, Bangdiwala I. Thrombophelibitis among oral and nonoral contraceptive users. Obstet Gynecol 1971; 38: 259-263
    PubMedGoogle Scholar
  • 5 Grounds M. Anovulants: thrombosis and other associated changes. Med J Aust 1974; 2: 440-446
    PubMedGoogle Scholar
  • 6 Royal College of Practitioners. Oral contraceptives venous thrombosis and varicose veins. J Gen Coll Practit 1978; 28: 393-399
    PubMedGoogle Scholar
  • 7 Diddle AW, Gardner WMH, Williamson PJ, Johnson JR, Hemphill JL, Godwin CW. Oral contraceptive steroids and thrombophlebitis. J Tenn Med Assoc 1978; 71: 22-26
    PubMedGoogle Scholar
  • 8 Porter JB, Hunter JR, Danielson DA, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease-recent experience. Obstet Gynecol 1982; 59: 299-302
    PubMedGoogle Scholar
  • 9 Porter JB, Hunter JR, Jick H, Stergachis A. Oral contrceptives and nonfatal vascular disease. Obstet Gynecol 1985; 66: 1-4
    PubMedGoogle Scholar
  • 10 Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 1986; 292: 526
    CrossrefPubMedGoogle Scholar
  • 11 Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol 1969; 90: 365-368
    CrossrefPubMedGoogle Scholar
  • 12 Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. BMJ 1969; 2: 651-657
    CrossrefPubMedGoogle Scholar
  • 13 Greenblatt DJ. A retrospective case-control study of diseases associated with oral contraceptive use. Am Heart J 1975; 89: 677-678
    CrossrefPubMedGoogle Scholar
  • 14 Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Oral contraceptives, smoking, and Am. J Epidemiol 1978; 108: 480-485
    PubMedGoogle Scholar
  • 15 Maguire MG, Tonascia J, Sartwell PE, Stolle PD, Tockman DS. (1979) Increased risk of thrombosis due to oral contraceptives: a further report. Am J Epidemiol 1979; 110: 188-195
    CrossrefPubMedGoogle Scholar
  • 16 Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet. Gynecol 1987; 69: 91-95
    PubMedGoogle Scholar
  • 17 WHO Collaborative Study. Cardiovascular disease and use of oral contraceptives. WHO Bulletin OMS 1989; 67: 417-423
    PubMedGoogle Scholar
  • 18 Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BMJ 1968; 2: 199-205
    CrossrefPubMedGoogle Scholar
  • 19 Stolley PD, Tonascia JA, Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP. Thrombosis with low-estrogen oral contraceptives Am. J Epidemiol 1975; 102: 197-208
    PubMedGoogle Scholar
  • 20 Katemdahl DA, Realini JP, Cohen PA. Oral contraceptive use and cardiovascular disease: is the relationship real or due to study bias?. J Fam Prac 1992; 35: 147-157
    PubMedGoogle Scholar
  • 21 Inman WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives a report to the committee on safety of drugs. BMJ 1970; 2: 203-209
    CrossrefPubMedGoogle Scholar
  • 22 Büttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980; 1: 1097-1101
    PubMedGoogle Scholar
  • 23 Glass R, Johson B, Vessey M. Accuracy of recall of histories of oral contraceptive use. Br J Prev Soc Med 1974; 28: 273-275
    PubMedGoogle Scholar
  • 24 Stolley PD, Tonascia JA, Sartwell PE, Tockman MS, Tonascia S, Rutledge A, Schinner R. Agreement rates between oral contraceptive users and prescribers in relation to drug use histories. Am J Epidemiol 1978; 107: 226-235
    CrossrefPubMedGoogle Scholar
  • 25 Sartwell PE. Oral contraceptives and thromboembolism: a further report. Am J Epidemiol 1971; 94: 192-201
    CrossrefPubMedGoogle Scholar
  • 26 Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case control study. Int J Epidemiol 1992; 21: 48-52
    CrossrefPubMedGoogle Scholar
  • 27 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457
    CrossrefPubMedGoogle Scholar
  • 28 Farmer RT, Preston TD. The risk of venous thromboembolism. associated with low oestrogen oral contraceptives. J Obstet Gyneacol 1995; 15: 195-200
    PubMedGoogle Scholar
  • 29 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 34: 1582-1588
    PubMedGoogle Scholar
  • 30 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593
    CrossrefPubMedGoogle Scholar
  • 31 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet 1995; 346: 1593-1596
    CrossrefPubMedGoogle Scholar
  • 32 Vademecum of Health Sciences of the Netherlands. Netherlands Central Bureau of Statistics. Ministery of Welfare Health and Cultural Affairs. Voorburg. 1994
    PubMedGoogle Scholar
  • 33 Anderson FA, Wheeler B, Goldberg RJ, Hosmer DW, Patwardam NA, Jovanovic B. et al A population-based perspective of the hospital incidence and case-fatality rates of deep venous thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933-938
    CrossrefPubMedGoogle Scholar
  • 34 Harrison’s Principles of Internal Medicine. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL. (eds) 13. New York: McGraw-Hill; 1994: 2033
  • 35 Kluft C. Oral contraceptives and hemostasis. Gynecol Endocrinol Suppl 1996; 10 (Suppl. 02) 49-57
    PubMedGoogle Scholar
  • 36 Jespersen J. Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives—a short review. Eur J Contracept Reprod Health Care 1996; 1: 03-11
    CrossrefPubMedGoogle Scholar
  • 37 Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
    CrossrefPubMedGoogle Scholar
  • 38 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506
    CrossrefPubMedGoogle Scholar
  • 39 Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrel RW. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112
    CrossrefPubMedGoogle Scholar
  • 40 Tait RC, Walker ID, Reitsma PH, Islam SI, McCall F, Poort SR, Conkie JA, Bertina RM. Prevalence of protein C deficiency in the healthy population. Thrombo Haemostas 1995; 73: 87-93
    PubMedGoogle Scholar
  • 41 Pabinger I, Schneider B. and the GTH Study Group on Natural Inhibitors Thrombotic risk of women with heriditary antithrombin IE-, protein C-and protein S deficiency taking oral contraceptive medication. Thrombo Haemostas 1994; 71: 548-552
    PubMedGoogle Scholar
  • 42 Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women?. BMJ 1996; 313: 1127-1130
    CrossrefPubMedGoogle Scholar
  • 43 Helmerhorst FM, Bloemenkamp KWM, Briët E, van der Meer FJM, Rosendaal FR, Vandenbroucke JP. Factor V Leiden mutation and contraception. Gynecol Endocrinol 1996; 10 (Suppl. 02) 85-87
    CrossrefPubMedGoogle Scholar
  • 44 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-1582
    CrossrefPubMedGoogle Scholar
  • 45 Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women Third-generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83-88
    CrossrefPubMedGoogle Scholar
  • 46 Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 05-13
    CrossrefPubMedGoogle Scholar
  • 47 Cramer DW. Safety of combined oral contraceptive pills. Lancet 1996; 347: 546
    CrossrefPubMedGoogle Scholar
  • 48 Lidegaand Ø. Oral contraceptives and venous thromboembolism: an epidemiological review. Eur J Contracept Reprod Health Care 1996; 1: 13-20
    CrossrefPubMedGoogle Scholar
  • 49 Herings RMC, de Boer A, Urquhart J, Leufkens HGM. Non-causal explanantions for the increased risk of venous thromboembolism among users of third-generation oral contraceptives. Pharmaepidemiol Drug Saf 1996; 5: S88 (abstract)
    PubMedGoogle Scholar
  • 50 Lewis MA, Spitzer WO, Heinemann LAJ, MacRae KD, Bruppacher R, Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ 1996; 312: 88-90
    CrossrefPubMedGoogle Scholar
  • 51 Lidegaard Ø, Edstrom B. Oral contraceptives and acute myocardial infarction: a case-control study (abstarct). Eur J Contracept Reprod Health Care 1996; 1: 74
    PubMedGoogle Scholar
  • 52 Vandenbroucke JP, Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR. Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands. Lancet 1996; 348: 401-402
    CrossrefPubMedGoogle Scholar
  • 53 Lidegaard Ø, Milson I. Oral contraceptives and thrombotic diseases: impact of new epidemiologic studies. Contraception 1996; 53: 135-139
    CrossrefPubMedGoogle Scholar
  • 54 Thomas SHL. Mortality from venous thromboembolism and myocardial infarction in young adults in England and Wales. Lancet 1996; 348: 402
    PubMedGoogle Scholar
  • 55 Wood AJJ Management of venous thromboembolism. NEJM 1996; 335: 1816-1828
    CrossrefPubMed
  • 56 Johnson BF, Manzo RA, Bergelin RO, Strandness Jr DE. Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one-to six year follow-up. J Vase Surg 1995; 21: 307-312
    CrossrefPubMedGoogle Scholar
  • 57 Vandenbroucke JP. Epidemiology — Annotation of Esbjerg I Consensus Conference. Gynaecol Endocrinol 1996; 10 (Suppl. 02) 5-7
    PubMedGoogle Scholar
  • 58 The Consensus Committee. Consensus Development Meeting Combined oral contraceptives and cardiovascular disease. Gynecol Endocrinol 1996; 10: 1-5
    PubMedGoogle Scholar